Cardiovascular benefits of paricalcitol in chronic kidney disease

被引：0
|
作者：
Jessica K. Edwards
机构：
来源：
Nature Reviews Nephrology | 2014年 / 10卷 / 12期
关键词：
D O I：
10.1038/nrneph.2014.200
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：675 / 675
相关论文
共 50 条
  • [1] Safety and tolerability of paricalcitol in patients with chronic kidney disease
    Dyer, Christopher A.
    EXPERT OPINION ON DRUG SAFETY, 2013, 12 (05) : 717 - 728
  • [2] Antiproteinuric effect of oral paricalcitol in chronic kidney disease
    Agarwal, R
    Acharya, M
    Tian, J
    Hippensteel, RL
    Melnick, JZ
    Qiu, P
    Williams, L
    Batlle, D
    KIDNEY INTERNATIONAL, 2005, 68 (06) : 2823 - 2828
  • [3] Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial
    Zoccali, Carmine
    Curatola, Giuseppe
    Panuccio, Vincenzo
    Tripepi, Rocco
    Pizzini, Patrizia
    Versace, Marica
    Bolignano, Davide
    Cutrupi, Sebastiano
    Politi, Raffaele
    Tripepi, Giovanni
    Ghiadoni, Lorenzo
    Thadhani, Ravi
    Mallamaci, Francesca
    HYPERTENSION, 2014, 64 (05) : 1005 - +
  • [4] Magnesium and Progression of Chronic Kidney Disease: Benefits Beyond Cardiovascular Protection?
    Sakaguchi, Yusuke
    Hamano, Takayuki
    Isaka, Yoshitaka
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2018, 25 (03) : 274 - 280
  • [5] Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
    D'Marco, Luis
    Checa-Ros, Ana
    Gamero, Dionilux
    Soto, Carlos
    Salazar, Juan
    Nava, Manuel
    Bermudez, Valmore
    Dapena, Fabiola
    HEALTHCARE, 2023, 11 (01)
  • [6] Paricalcitol for pre-dialysis stages of chronic kidney disease
    Almirall, Jaume
    Isabel Bolos, M.
    NEFROLOGIA, 2012, 32 (02): : 250 - 251
  • [7] Oral paricalcitol as antiprotein uric agent in chronic kidney disease
    de Lorenzo, Alberto
    Salanova, Laura
    Bomback, Andrew S.
    Moya, Maria
    Coronel, Francisco
    Bernis, Carmen
    Sanchez-Tomero, Jose A.
    Alvarez, Vicente
    NEFROLOGIA, 2013, 33 (05): : 709 - 715
  • [8] Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease
    Cheng, S
    Coyne, D
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (05) : 617 - 621
  • [9] Does paricalcitol reduce proteinuria in patients with chronic kidney disease?
    Yoshiki Nishizawa
    Tetsuo Shoji
    Nature Clinical Practice Nephrology, 2006, 2 : 352 - 353
  • [10] Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease. A meta-analysis
    Hu, X.
    Shang, J.
    Yuan, W.
    Zhang, S.
    Jiang, Y.
    Zhao, B.
    Duan, Y.
    Xiao, J.
    Zhao, Z.
    HERZ, 2018, 43 (06) : 518 - 528
12345